To better address the evolving risk of type 2 circulating vaccine-derived poliovirus (cVDPV2), GPEI partners are working to deploy an additional innovative tool – novel oral polio vaccine type 2 (nOPV2). The vaccine is a modified version of the existing type 2 monovalent OPV (mOPV2), which clinical trials have shown provides comparable protection against poliovirus while being more genetically stable and less likely to revert into a form which can cause paralysis in low immunity settings. The vaccine’s increased genetic stability means there is also a reduced risk of seeding new cVDPV2 outbreaks, compared to mOPV2.

nOPV2 will be deployed under WHO’s Emergency Use Listing procedure (EUL) to enable its rapid field availability. Even after meeting rigorous EUL criteria for safety and immunogenicity, nOPV2’s performance in the field will be closely monitored in line with EUL standards and data collection will continue, with the ultimate goal of WHO prequalification.

Key Resources

  • GPEI polio outbreak response training
  • Interim Guidance on the use of Novel Oral Polio Vaccine Type 2 (nOPV2) for the response to Type 2 Circulating Vaccine-Derived Poliovirus (cVDPV2) during the Initial Use Period (Addendum to the Standard Operating Procedures for Response to a Poliovirus Event or Outbreak, version 3. 1) | English | French |
  • Novel OPV2 (nOPV2) Management, Monitoring, Removal and Disposal (in 50 dose vials with VVM type 2) | English | French |
  • Polio Field and Laboratory Surveillance Requirements in the Context of nOPV2 Use | English| French |
  • Novel oral polio vaccine type 2 (nOPV2) Vaccine-Related Event (VRE) Response Plan | English | French | Arabic |
  • Guide for Surveillance of Adverse Events of Special Interest (AESI) during novel Oral Polio Vaccine type 2 (nOPV2) Use | English |

Media center

Additional Resources and Updates